Posted by Michael Wonder on 27 Jul 2021
FDA approves Keytruda (pembrolizumab) for treatment of patients with high-risk early stage triple negative breast cancer in combination with chemotherapy as neo-adjuvant treatment, then continued as single agent as adjuvant treatment after surgery
27 July 2021 - Keytruda is now approved in the US for 30 indications.
Merck today announced that the U.S. FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with high risk early stage triple negative breast cancer in combination with chemotherapy as neo-adjuvant treatment and then continued as a single agent as adjuvant treatment after surgery, based on the Phase 3 KEYNOTE-522 trial.
